WHO Study Group on cell substrates for production of biologicals, Geneva, Switzerland, 11–12 June 2007

• Published in: Biologicals Vol. 36; no. 3; pp. 203 - 211
• Main Authors: Knezevic, I., Stacey, G., Petricciani, J.
• Format: Journal Article Conference Proceeding
• Language: English
• Published: England Elsevier Ltd 01.05.2008
• Subjects: Animals; Biological Products - analysis; Biological Products - isolation & purification; Cell substrates; Chemistry, Pharmaceutical - trends; Continuous cell lines; DNA - chemistry; Humans; Quality Control; Recommendations; Reference Standards; Switzerland; Vaccines; Vaccines - chemistry; WHO Study Group; World Health Organization; Switzerland; Recommendations; Continuous cell lines; Vaccines; WHO Study Group; Cell substrates
• ISSN: 1045-1056; 1095-8320
• DOI: 10.1016/j.biologicals.2007.11.005

For many years, the World Health Organization (WHO) has provided global leadership in defining technical specifications for quality assurance and safety of biological medicines produced in cell substrates. Current WHO requirements for the use of animal cells as substrates for production of vaccines and other biologicals were adopted by the WHO Expert Committee on Biological Standardization in 1996 (WHO TRS 878). Since then, significant progress especially in the development of vaccines in novel continuous cell lines of mammalian origin as well as in insect cells has been made and consequently there is an increasing need for the re-evaluation of existing criteria for the acceptability of such cell lines. In addition there is also a need to consider new issues in cell substrate safety arising from these new cell types and developments in technology and scientific knowledge. In response to these demands, the WHO Study Group on Cell Substrates was formed in 2006 to initiate revision of WHO requirements and to address the need for further research in this area. At its second meeting on 11–12 June 2007, the Study Group reviewed scientific data that would form the basis for new recommendations and made a number of proposals for further investigations. The Study Group is working on the preparation of a revised WHO document, and a broad consultation with regulators, manufacturers, and other relevant parties is planned for 2008.